EDG-5506 is under clinical development by Edgewise Therapeutics and currently in Phase II for Duchenne Muscular Dystrophy. According to GlobalData, Phase II drugs for Duchenne Muscular Dystrophy have a 65% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how EDG-5506’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

EDG-5506 overview

EDG-5506 is under development for the treatment of Duchenne muscular dystrophy, Becker muscular dystrophy, Limb girdle muscular dystrophy (LGMD) and McArdle disease. It is administered through oral route. it acts by targeting myosin ATPase.

Edgewise Therapeutics overview

Edgewise Therapeutics carries out the discovery, development and commercialization of innovative products to treat severe and rare muscle disorders. The company’s product portfolio includes EDG-5506, EDG-5440 and EDG-002. Its products are used in various therapeutic areas such as duchenne, limb-girdle and becker muscular dystrophy, hypertrophic cardiomyopathy, McArdle disease (also known as Glycogen storage disease type V or GSDV) and rare neuromuscular disease. Edgewise Therapeutics collaborates with a network of experts who advise and support its development activities. The company utilizes translatable systems to identify small-molecule precision medicines which regulate key proteins in muscle tissue. Edgewise Therapeutics is headquartered in Boulder, Colorado, the US.

For a complete picture of EDG-5506’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.